Vivos gives PAO $0.41 stock, 150K options

Vivos Therapeutics, Inc. (VVOS) reported that Principal Accounting Officer Bradford K. Amman received equity awards on July 31, 2026.

Rhea-AI Filing Summary

Vivos Therapeutics, Inc. (VVOS) reported that Principal Accounting Officer Bradford K. Amman received equity awards on July 31, 2026. He was granted 150,000 stock options with an exercise price of $0.41 per share, expiring July 31, 2036, and a separate grant of 250,000 shares of common stock at $0.41 per share. Following these grants, he holds 326,533 stock options and 250,080 shares of common stock directly. The option grant was made under the company’s 2024 Omnibus Equity Incentive Plan and is scheduled to vest at a stated rate of 25,000 shares per month from November 1, 2026 through April 1, 2026.

Insider Trade Summary

Grant/Award: 400,000 shares

Grant/Award 2 txns

Insider Amman Bradford K.

Role Principal Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	150,000	$0.41	$61K
Grant/Award	Common Stock	250,000	$0.41	$103K

Holdings After Transaction: Stock Option (Right to Buy) — 326,533 contracts (Direct); Common Stock — 250,080 shares (Direct)

Footnotes (1)

1. F1. On July 31, 2026 (the "Grant Date"), the Reporting Person received a grant of 150,000 stock options, which grant was made under the Issuer's 2024 Omnibus Equity Incentive Plan. Stock options shall vest and become exercisable at the rate of 25,000 shares per month from November 1, 2026 through April 1, 2026.

Key Figures

Stock options granted: 150,000 options Option exercise price: $0.41 per share Option expiration date: July 31, 2036 +4 more

7 metrics

Stock options granted 150,000 options Grant on July 31, 2026 under 2024 Omnibus Equity Incentive Plan

Option exercise price $0.41 per share Exercise price for 150,000 stock options granted July 31, 2026

Option expiration date July 31, 2036 Expiration date of 150,000 stock options

Common stock granted 250,000 shares Common stock award on July 31, 2026 at $0.41 per share

Common stock holdings after grant 250,080 shares Direct common stock ownership following July 31, 2026 grant

Option holdings after grant 326,533 options Total stock options directly held after July 31, 2026 grant

Monthly vesting amount 25,000 shares per month Stated vesting rate from November 1, 2026 through April 1, 2026

Key Terms

Stock Option (Right to Buy), Omnibus Equity Incentive Plan, vesting, Principal Accounting Officer

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Omnibus Equity Incentive Plan financial

"made under the Issuer's 2024 Omnibus Equity Incentive Plan"

A single, company-wide plan that lets a business grant different kinds of stock-based pay — such as stock options, shares that vest over time, or other equity awards — to employees, directors and consultants. It matters to investors because it determines how much of the company can be paid out in shares, how quickly those shares enter the market, and how well employees are motivated to grow the business; think of it as a toolbox or menu for paying with ownership stakes that can dilute existing holders and affect company performance.

vesting financial

"Stock options shall vest and become exercisable at the rate of 25,000 shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Principal Accounting Officer financial

"officer_title": "Principal Accounting Officer""

The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did VVOS grant to Bradford K. Amman on July 31, 2026?

On July 31, 2026, VVOS granted 150,000 stock options at an exercise price of $0.41 per share and a separate award of 250,000 shares of common stock at $0.41 per share to Principal Accounting Officer Bradford K. Amman.

What are the key terms of Bradford K. Amman’s VVOS stock options?

Bradford K. Amman received 150,000 stock options on July 31, 2026 with an exercise price of $0.41 per share, expiring on July 31, 2036. The options were granted under Vivos Therapeutics’ 2024 Omnibus Equity Incentive Plan and have a stated monthly vesting schedule beginning November 1, 2026.

How many VVOS shares and options does Bradford K. Amman hold after these transactions?

After the reported grants, Bradford K. Amman directly holds 250,080 shares of common stock and 326,533 stock options of Vivos Therapeutics, Inc., as stated in the Form 4 data.

At what price were Bradford K. Amman’s VVOS equity awards valued?

Both the 150,000 stock options and the 250,000 common shares granted to Bradford K. Amman on July 31, 2026 were reported at $0.41 per share in the Form 4 filing.

Under which plan were the VVOS stock options granted to Bradford K. Amman?

The 150,000 stock options granted to Bradford K. Amman on July 31, 2026 were issued under Vivos Therapeutics, Inc.’s 2024 Omnibus Equity Incentive Plan, according to the Form 4 footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/26/2026 - 04:11 PM EDT Accepted by SEC EDGAR 08/26/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Amman Bradford K.

(Last) (First) (Middle)

7921 SOUTHPARK PLAZA,

SUITE 210

(Street)

LITTLETON COLORADO 80120

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vivos Therapeutics, Inc. [ VVOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/31/2026		A		250,000	A	$0.41	250,080	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.41	07/31/2026		A		150,000		(1)	07/31/2036	Common Stock	150,000	$0.41	326,533	D

Explanation of Responses:

1. On July 31, 2026 (the "Grant Date"), the Reporting Person received a grant of 150,000 stock options, which grant was made under the Issuer's 2024 Omnibus Equity Incentive Plan. Stock options shall vest and become exercisable at the rate of 25,000 shares per month from November 1, 2026 through April 1, 2026.

	/s/ Bradford K. Amman	08/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)